TALVEY
GrowthBsAbBLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALVEY (talquetamab) is a bispecific antibody (BSAB) approved by the FDA in August 2023 for hematologic malignancies. It binds simultaneously to CD3 on T cells and GPRC5D on tumor cells, redirecting immune attack to cancer. The mechanism leverages dual-targeting to enhance T-cell mediated cytotoxicity against malignant B cells.
Growth
As a 2023 approval in growth phase, TALVEY represents an emerging revenue driver for J&J's hematology franchise with expanding commercial team buildout opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Johnson & Johnson is hiring 2 roles related to this product
Worked on TALVEY at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.